The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Oxford Immunotec Global PLC | COM | G6855A103 | 24,761 | 2,153,092 | SH | DFND | 2,153,092 | 0 | 0 | ||
| VBI Vaccines Inc. | COM | 91790E102 | 12,129 | 4,971,091 | SH | DFND | 4,971,091 | 0 | 0 | ||
| Sientra Inc. | COM | 82621J105 | 16,166 | 2,730,765 | SH | DFND | 2,730,765 | 0 | 0 | ||
| Nanostring Technologies Inc. | COM | 63009R109 | 58,243 | 3,959,440 | SH | DFND | 3,959,440 | 0 | 0 | ||
| TetraLogic Pharmaceuticals Corporation | COM | 88165U109 | 8,035 | 4,644,705 | SH | DFND | 4,644,705 | 0 | 0 | ||
| Catabasis Pharmaceuticals Inc. | COM | 14875P107 | 21,827 | 2,752,488 | SH | DFND | 2,752,488 | 0 | 0 | ||
| Aerie Pharmaceuticals Inc. | COM | 00771V108 | 1,534 | 63,017 | SH | DFND | 63,017 | 0 | 0 | ||